GlaxoSmithKline and NeuroSearch to Investigate CNS Diseases
Business Review Editor
Abstract
GlaxoSmithKline formed a 5 year research and development alliance with NeuroSearch for several research programs for treating CNS diseases such as depression, anxiety and schizophrenia in a deal worth up to €82 M.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.